Antiemetic drugs are essential therapies used to prevent and treat nausea and vomiting associated with chemotherapy, radiation therapy, surgery, pregnancy-related nausea, gastroenteritis, migraine, motion sickness, opioid use, and other gastrointestinal or vestibular disorders. The category spans serotonin 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, dopamine antagonists, antihistamines, anticholinergics, corticosteroids, cannabinoids, and fixed-dose or extended-release regimens designed to improve symptom control and patient adherence. Demand is supported by the rising global burden of cancer treatment, expanding surgical volumes, greater use of outpatient and ambulatory care, and heightened clinical emphasis on quality of life, hydration status, nutrition, and treatment continuity. In oncology, guideline-based antiemetic prophylaxis remains a critical component of chemotherapy and radiotherapy supportive care, particularly as cancer care increasingly combines highly emetogenic regimens, immunotherapy, targeted agents, and complex multimodal protocols. In perioperative care, antiemetic strategies are central to reducing postoperative nausea and vomiting, which can delay discharge and increase unplanned clinical interventions. The industry is also shaped by regulatory scrutiny, drug safety monitoring, generic competition, formulation innovation, and payer pressure for cost-effective prescribing. As healthcare systems prioritize evidence-based supportive care, antiemetic drugs are positioned as clinically important, high-utility therapies across hospital, oncology, emergency, obstetric, pediatric, and primary care settings.

Transformative Shifts in the Antiemetic Drugs Landscape

The antiemetic drugs landscape is being reshaped by the shift from reactive symptom treatment to proactive, risk-stratified prevention. Clinical protocols increasingly match antiemetic regimens to emetogenic risk, patient history, age, pregnancy status, comorbidities, drug interactions, and prior response, improving the precision of therapy selection. Oncology supportive care has moved toward combination prophylaxis, including 5-HT3 antagonists, NK1 antagonists, dexamethasone, and olanzapine-based approaches for selected high-risk chemotherapy settings, reflecting evidence that multi-pathway control improves outcomes for acute and delayed nausea and vomiting. At the same time, ambulatory surgery centers and outpatient oncology clinics are increasing the need for oral, transdermal, orally disintegrating, and long-acting antiemetic formulations that fit same-day care models. Safety differentiation is also becoming more important as clinicians consider QT prolongation, extrapyramidal symptoms, sedation, anticholinergic effects, pregnancy safety data, and geriatric vulnerability. Another major transformation is the growing role of value-based care, where reducing avoidable emergency visits, dehydration, treatment interruptions, and postoperative delays directly supports health system performance. The competitive environment is also influenced by patent expiries, generics, oncology treatment expansion that indirectly increases supportive care needs, and tighter procurement systems in hospitals. Together, these shifts are making clinical evidence, formulation convenience, tolerability, supply reliability, and guideline alignment decisive factors in antiemetic drug adoption.

Cumulative Impact of Artificial Intelligence on Antiemetic Care

Artificial intelligence is beginning to influence antiemetic drug development, clinical decision support, pharmacovigilance, and care pathway optimization. In oncology, AI-enabled risk models can analyze treatment regimen, patient demographics, prior nausea history, laboratory values, comorbidities, concomitant medications, and real-world outcomes to identify individuals at elevated risk for chemotherapy-induced nausea and vomiting. This can support more tailored prophylaxis and earlier intervention, particularly for delayed nausea, which is often underreported compared with acute vomiting. In perioperative care, predictive analytics can strengthen postoperative nausea and vomiting risk assessment by integrating anesthesia type, opioid exposure, surgical duration, sex, smoking status, motion sickness history, and prior postoperative nausea. AI also supports drug safety surveillance by detecting adverse event patterns, medication interaction signals, and off-label use trends across electronic health records, spontaneous reporting systems, and claims datasets. In research and development, machine learning may help identify receptor-binding patterns, optimize formulation attributes, and prioritize candidate combinations, although clinical validation and regulatory acceptance remain essential. The cumulative impact of AI is therefore not a replacement for clinician judgment but an evidence-enhancing layer that can improve prophylaxis selection, reduce symptom burden, support adherence, and generate real-world evidence. Successful deployment will depend on transparent algorithms, diverse datasets, privacy safeguards, interoperability, and ongoing monitoring for bias in vulnerable populations such as children, pregnant patients, older adults, and people receiving complex oncology regimens.

Key Regional Insights for Antiemetic Drugs

Asia-Pacific is a high-priority region for antiemetic drugs because of expanding cancer diagnosis and treatment capacity, large surgical volumes, rising healthcare expenditure in several economies, and broader access to oncology medicines and supportive care protocols. China, India, Japan, South Korea, Australia, and ASEAN markets show differentiated demand patterns, with mature reimbursement and guideline use in Japan, South Korea, and Australia, and rapid access expansion in China, India, and Southeast Asia. Europe benefits from established clinical guidelines, pharmacovigilance systems, broad use of generics, and structured oncology and perioperative care pathways, while national reimbursement differences influence access to newer antiemetic combinations and long-acting formulations. North America remains characterized by strong oncology supportive care guideline adoption, advanced hospital pharmacy systems, high outpatient chemotherapy utilization, and extensive use of perioperative risk assessment in surgical settings. The United States and Canada continue to emphasize evidence-based prescribing, opioid-sparing perioperative pathways, and patient-reported symptom management. Latin America is shaped by growing cancer care infrastructure, unequal access between urban and rural populations, and public-sector procurement priorities, with Brazil and Mexico playing central roles in regional oncology and hospital demand. Africa presents a fragmented environment, where access to antiemetic drugs is tied to essential medicines availability, cancer treatment expansion, surgical care capacity, and supply chain resilience; demand is strongest in urban referral hospitals but constrained by affordability and infrastructure gaps in many settings. The Middle East is advancing through investments in tertiary hospitals, cancer centers, medical tourism hubs, and formulary modernization, especially in high-income Gulf markets.

Key Group Insights Across NATO, G7, BRICS, EU, ASEAN, and GCC

NATO member countries overlap substantially with North America and Europe and are often characterized by advanced hospital procurement systems, established emergency and surgical services, strong pharmaceutical quality standards, and resilient medicine supply requirements. G7 countries generally show high clinical protocol adherence, established cancer and perioperative care pathways, and mature regulatory oversight, making evidence quality, safety, and real-world outcomes especially important for product positioning. BRICS countries collectively represent a large and diverse demand base, combining major oncology treatment expansion in China, India, and Brazil with public-sector cost containment, local production priorities, and domestic pharmaceutical manufacturing capacity. The European Union reflects a highly regulated environment with strong pharmacovigilance, cross-country clinical guideline influence, and broad generic utilization; however, individual national health technology assessment and reimbursement processes continue to shape uptake of newer antiemetic regimens. ASEAN demand for antiemetic drugs is supported by expanding hospital networks, increasing chemotherapy access, growth in medical tourism, and broader use of outpatient care, though access varies significantly between higher-income urban centers and lower-resource settings. The GCC is distinguished by major investments in oncology centers, advanced surgical care, and hospital formularies, creating favorable conditions for guideline-based antiemetic prophylaxis and premium formulations where reimbursement supports adoption. Across these groups, the most consistent themes are the need for affordable access, reliable supply, clinically validated combinations, and formulations that align with outpatient oncology and same-day surgical workflows.

Key Country Insights for Antiemetic Drugs

China is experiencing strong clinical need as oncology diagnosis, chemotherapy access, and hospital modernization continue to expand, with policy attention on drug affordability and volume-based procurement affecting category dynamics. The United States is a major center for antiemetic drug utilization due to extensive oncology treatment, ambulatory surgery, emergency care, and strong adoption of supportive care guidelines, while Japan has sophisticated antiemetic use, especially in oncology, supported by aging demographics, high clinical protocol adherence, and advanced hospital systems. India combines large patient need, domestic manufacturing strength, and increasing oncology infrastructure, while affordability and regional care disparities remain decisive. Germany, the United Kingdom, France, Italy, and Spain demonstrate mature use of antiemetic protocols in oncology and perioperative care, with national reimbursement systems and generic availability influencing prescribing behavior; Germany and France maintain strong hospital pharmacy governance, while the United Kingdom places emphasis on guideline-driven quality and cost-effectiveness. Australia reflects strong evidence-based prescribing and broad access through structured reimbursement, while South Korea combines advanced cancer care, high technology adoption, and disciplined reimbursement review, supporting structured use of both established and newer antiemetic therapies. Canada emphasizes standardized care pathways, formulary evaluation, and equitable access across provincial systems, while Russia has demand tied to oncology and surgical care capacity, with supply chain complexity and regulatory localization influencing access. Brazil is central to Latin American antiemetic demand, supported by large oncology and hospital networks, with procurement and affordability shaping product selection. Mexico shows growing demand linked to expanding cancer care and hospital services, though public-private access differences remain important.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize guideline-aligned evidence generation that demonstrates meaningful reductions in nausea, vomiting, rescue medication use, dehydration-related interventions, treatment interruptions, and delayed discharge after surgery. Product strategies should focus on differentiated tolerability, convenient dosing, extended coverage for delayed symptoms, and patient-friendly formulations such as orally disintegrating, transdermal, and long-acting options. Manufacturers and distributors should strengthen supply reliability for essential antiemetics, as shortages can directly disrupt chemotherapy and perioperative protocols. Market access teams should tailor evidence packages to payer expectations, emphasizing real-world outcomes, pharmacoeconomic value, and fit within oncology and surgical care pathways. Clinical education should address underrecognized nausea burden, appropriate multi-drug prophylaxis, safety considerations, and special population needs in pediatrics, pregnancy, geriatrics, and patients with cardiac risk. Digital health integration, including symptom tracking and AI-supported risk stratification, can improve timely intervention and generate post-market evidence. Companies should also pursue region-specific strategies: affordability and availability in emerging markets, formulation and safety differentiation in mature markets, and hospital formulary alignment across procurement-driven systems. Above all, competitive advantage will depend on combining clinical credibility, regulatory compliance, patient-centered design, and resilient manufacturing with a clear commitment to measurable improvements in supportive care outcomes.

Research Methodology

This executive summary is built from a structured review of verified secondary sources and accepted clinical knowledge related to antiemetic pharmacology, oncology supportive care, perioperative nausea and vomiting management, regulatory standards, and regional healthcare system dynamics. The methodology includes triangulation of evidence from clinical guidelines, peer-reviewed literature, drug labeling and safety communications, public health datasets, healthcare utilization indicators, national and regional policy documents, and pharmacovigilance resources. The analysis focuses on qualitative industry dynamics, therapeutic use patterns, regulatory and reimbursement considerations, technology influence, and regional access factors. It intentionally excludes market sizing, share analysis, and forecasting to maintain alignment with evidence-based strategic interpretation rather than speculative quantification. Regional, group, and country insights were developed by comparing healthcare infrastructure maturity, oncology and surgical care development, formulary and procurement practices, reimbursement environments, and access constraints. AI impact analysis was assessed through documented applications in risk prediction, clinical decision support, real-world evidence generation, drug discovery, and safety surveillance, with emphasis on implementation requirements such as validation, transparency, interoperability, and bias monitoring. All findings were synthesized to support decision-making for pharmaceutical, healthcare, and life sciences stakeholders seeking a clear understanding of the antiemetic drugs landscape.

Conclusion

Antiemetic drugs remain a foundational component of modern supportive care, enabling patients to continue cancer therapy, recover more efficiently after surgery, avoid preventable complications, and maintain nutrition, hydration, and quality of life. The industry is evolving from broad symptom control toward personalized prevention, evidence-based combination regimens, safety-led differentiation, and formulations suited to outpatient care. Regional dynamics vary widely, with mature markets emphasizing guideline adherence and value-based outcomes, while emerging markets prioritize access, affordability, infrastructure expansion, and supply continuity. Artificial intelligence adds a new layer of opportunity by improving risk prediction, real-world evidence generation, pharmacovigilance, and patient monitoring, provided that implementation is clinically validated and ethically governed. For industry leaders, the strongest opportunities lie in therapies and strategies that address delayed nausea, improve adherence, reduce care disruption, and integrate seamlessly into oncology, surgical, emergency, and primary care pathways. Sustained success will require balancing innovation with affordability, safety with convenience, and global strategy with local access realities.

Product Code: MRR-C002B1C996F2

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Antiemetic Drugs Market, by Drug Class

7.1. Introduction
7.2. Corticosteroids
7.3. Dopamine Antagonists
7.4. Neurokinin 1 Receptor Antagonists
7.5. Serotonin 5-HT3 Receptor Antagonists

8. Antiemetic Drugs Market, by Indication

8.1. Introduction
8.2. Chemotherapy-Induced Nausea And Vomiting
8.3. Post-Operative Nausea And Vomiting
8.4. Radiation-Induced Nausea And Vomiting

9. Antiemetic Drugs Market, by Route Of Administration

9.1. Introduction
9.2. Intravenous
9.3. Oral

10. Antiemetic Drugs Market, by End User

10.1. Introduction
10.2. Clinics
10.3. Home Care Settings
10.4. Hospitals

11. Antiemetic Drugs Market, by Molecule Type

11.1. Introduction
11.2. Small Molecule Drugs
11.3. Biologic Drugs
11.4. Cannabinoid Based Drugs

12. Antiemetic Drugs Market, by Distribution Channel

12.1. Introduction
12.2. Offline
12.3. Online

13. Antiemetic Drugs Market, by Region

13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East

14. Antiemetic Drugs Market, by Group

14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC

15. Antiemetic Drugs Market, by Country

15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain

16. Competitive Landscape

16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
- 16.3.1. Concentration Ratio (CR)
- 16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025

17. Company Profiles

17.1. Abbott Laboratories
17.2. Alkem Laboratories Limited
17.3. Amgen Inc
17.4. Astellas Pharma Inc
17.5. AstraZeneca PLC
17.6. Aurobindo Pharma Limited
17.7. Baxter International Inc
17.8. Boehringer Ingelheim International GmbH
17.9. Cipla Limited
17.10. Dr Reddys Laboratories Limited
17.11. Eagle Pharmaceuticals Inc
17.12. Eisai Co Ltd
17.13. Eli Lilly and Company
17.14. F Hoffmann-La Roche Ltd
17.15. Fresenius Kabi AG
17.16. Glenmark Pharmaceuticals Limited
17.17. GSK plc
17.18. Hikma Pharmaceuticals PLC
17.19. Johnson & Johnson
17.20. Lupin Limited
17.21. Merck & Co Inc
17.22. Novartis AG
17.23. Pfizer Inc
17.24. Sun Pharmaceutical Industries Limited
17.25. Takeda Pharmaceutical Company Limited
17.26. Teva Pharmaceutical Industries Limited
17.27. Torrent Pharmaceuticals Limited
17.28. Viatris Inc
17.29. Zydus Lifesciences Limited

Product Code: MRR-C002B1C996F2

LIST OF FIGURES

FIGURE 1. GLOBAL ANTIEMETIC DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTIEMETIC DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTIEMETIC DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTIEMETIC DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ANTIEMETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL ANTIEMETIC DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

TABLE 1. GLOBAL ANTIEMETIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NEUROKININ 1 RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NEUROKININ 1 RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NEUROKININ 1 RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL POST-OPERATIVE NAUSEA AND VOMITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL POST-OPERATIVE NAUSEA AND VOMITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL POST-OPERATIVE NAUSEA AND VOMITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL RADIATION-INDUCED NAUSEA AND VOMITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL RADIATION-INDUCED NAUSEA AND VOMITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL RADIATION-INDUCED NAUSEA AND VOMITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BIOLOGIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL BIOLOGIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL BIOLOGIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CANNABINOID BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CANNABINOID BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CANNABINOID BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 63. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 64. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 65. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 66. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 67. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 68. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 70. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 71. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 72. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 73. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 74. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 91. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 92. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 95. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. NATO ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 106. NATO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 107. NATO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. NATO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. NATO ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 110. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. G7 ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 113. G7 ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 114. G7 ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 115. G7 ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. G7 ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 117. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 120. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 121. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 122. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 124. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 134. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 135. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 136. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 138. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. GCC ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 141. GCC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 142. GCC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. GCC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. GCC ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 145. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. CHINA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 148. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 149. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 150. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 153. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 154. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 156. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. JAPAN ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 162. JAPAN ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 163. JAPAN ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 164. JAPAN ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. JAPAN ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. JAPAN ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 167. JAPAN ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. INDIA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 169. INDIA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 170. INDIA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 171. INDIA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. INDIA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. INDIA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 174. INDIA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 175. GERMANY ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 176. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 177. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 178. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 179. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 181. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 183. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 184. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 185. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 186. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 188. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 189. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 190. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 191. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 192. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 195. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 196. FRANCE ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 197. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 198. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 199. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 200. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 202. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 204. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 205. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 206. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 208. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 209. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. ITALY ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 211. ITALY ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 212. ITALY ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 213. ITALY ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 214. ITALY ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. ITALY ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 216. ITALY ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 217. CANADA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 219. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 220. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 221. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 223. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 224. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 225. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 226. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 227. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 228. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 229. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 230. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 231. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 232. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 233. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 234. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 235. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 237. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 238. MEXICO ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 239. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 240. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 241. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 242. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 243. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 244. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 245. SPAIN ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 246. SPAIN ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 247. SPAIN ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 248. SPAIN ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. SPAIN ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 250. SPAIN ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 251. SPAIN ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 252. GLOBAL ANTIEMETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 253. GLOBAL ANTIEMETIC DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION